Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients

Hepatology Research

Volumn 44, Issue 10, 2014, Pages E163-E171

  Sezaki, Hitomi ^a   Suzuki, Fumitaka ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Fukushima, Taito ^a   Hara, Tasuku ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis; Hepatitis C virus; Pegylated interferon; Ribavirin; Telaprevir

Indexed keywords

CREATININE; HEMOGLOBIN; INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; URIC ACID; VIRUS RNA;

ADULT; ADVERSE DRUG REACTION; AGE; ANEMIA; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS C; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY VIROLOGICAL RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; SEX; SKIN DISEASE; SUSTAINED VIROLOGICAL RESPONSE RATE; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VIRUS LOAD; VIRUS RNA BLOOD LEVEL;

EID: 84907861615     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12268     Document Type: Article

References (31)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1): 17-24.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
5. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med 2002; 347: 975-982.
6. Hadziyannis SJ, Sette H, Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
7. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Kanwal F, Hoang T, Spiegel BM etal. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-1749.
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The obsvirc, metavir, clinivir, and dosvirc groups. Lancet 1997; 349: 825-832.
10. Conjeevaram HS, Fried MW, Jeffers LJ etal. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
11. Tsubota A, Chayama K, Ikeda K etal. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
12. Sezaki H, Suzuki F, Kawamura Y etal. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-1324.
13. Lin C, Kwong AD, Perni RB. Discovery and development of vx-950, a novel, covalent, and reversible inhibitor of hepatitis C virus ns3.4a serine protease. Infect Disord Drug Targets 2006; 6: 3-16.
14. Hezode C, Forestier N, Dusheiko G etal. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
15. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
16. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
17. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
18. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
19. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134-142.
20. Suzuki F, Suzuki Y, Akuta N etal. Influence of itpa polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-421.
21. Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 7-17.
22. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
23. Akuta N, Suzuki F, Sezaki H etal. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
24. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput snp typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477.
25. Suzuki A, Yamada R, Chang X etal. Functional haplotypes of padi4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
26. Suzuki F, Akuta N, Suzuki Y etal. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (mp-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009; 39: 1056-1063.
27. Reesink HW, Zeuzem S, Weegink CJ etal. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
28. Sarrazin C, Kieffer TL, Bartels D etal. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
29. Lawitz E, Rodriguez-Torres M, Muir AJ etal. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-169.
30. Chayama K, Hayes CN, Abe H etal. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
31. Akuta N, Suzuki F, Hirakawa H etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 57: 421-429.